Induction of Anti-Tumor Immunity by Concomitant Cell Therapy and Trifunctional Bispecific Antibody Anti-(CD3 X Anti-EpCAM)dendritic cellselectroporationnonviral vectorsadenovirusretrovirusGenetic modification of dendritic cells (DCs) with recombinant vectors encoding tumor antigens may aid in ...
The broader clinical use of bispecific T cell engagers for inducing anti-tumour toxicity is hindered by their on-target off-tumour toxicity and the associated neurotoxicity and cytokine-release syndrome. Here we show that the off-tumour toxicity of a sup
Although the primary aim of cytotoxic therapy is to induce tumor cell death, some tumor cells take other fates such as senescence and quiescence, which allow them to continue the secretion of TDEs that promote the malignant progression of surviving viable tumor cells30,31. Current strategies to ...
Combinatorial therapy has become another mainstream strategy. The current focus is on the use of azacitidine with or without venetoclax in hematological tumors.175,198,199The use of chemotherapy increases the overall “eat me” signal of tumors, which synergizes with blockade of the “don’t eat ...
Although the primary aim of cytotoxic therapy is to induce tumor cell death, some tumor cells take other fates such as senescence and quiescence, which allow them to continue the secretion of TDEs that promote the malignant progression of surviving viable tumor cells30,31. Current strategies to ...
During this process, several factors in the tumor microenvironment (TME) differentially regulate the activity and functional effects of tumor-infiltrating T cells. Cytotoxic T cells, or CD8+ T cells detect tumor or infected cells by binding their T cell receptor (TCR), specifically to the MHC ...
Enhanced lysis by bispecific oncolytic measles viruses simultaneously using HER2/neu or EpCAM as target receptors. Mol Ther Oncolytics. 2016;3:16003. Article PubMed PubMed Central Google Scholar Guillerme JB, Gregoire M, Tangy F, Fonteneau JF. Antitumor virotherapy by attenuated measles virus (...
The IL-15 TriKE is specific and fully active against EpCAM bearing cancer cells, inducing selective NK cell degranulation. Additionally, the TriKE is functionally superior to the BiKE and capable of stimulating NK proliferation and expansion in a manner similar to exogenous IL-15 despite its ...
The ROS sensitive combination therapy achieved synergistic antitumor efficacy in a melanoma cancer model, accompanied by enhanced T cell immune responses. Taking advantages of drug delivery systems to simultaneously block CD47 and SIRPα could also produce good therapeutic effects. Nie et al. [71] ...
In Vivo Efficacy of Anti-CXCL13 Antibody Therapy in Cynomolgus Monkey In the normal immune response, CXCL13 and its receptor CXCR5 are involved in the homing of B cells and germinal center formation. Ccynomolgus monkeys Immunized with T-cell-dependent antibody response (TDAR) of keyhole limpet ...